X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Moderna To introduce The Fusion Of COVID-19 And Flu Booster

    September May See Advent of Revised COVID-19 Booster Shots

    First Patient Adopting TAC-001 Has Been Announced By Tallac

    First Patient Adopting TAC-001 Has Been Announced By Tallac

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Continues To Deal With Issues With Expedited Clearance

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Merck and Orion Announce Global Collaboration for Oncology Drug

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Moderna To introduce The Fusion Of COVID-19 And Flu Booster

    September May See Advent of Revised COVID-19 Booster Shots

    First Patient Adopting TAC-001 Has Been Announced By Tallac

    First Patient Adopting TAC-001 Has Been Announced By Tallac

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Continues To Deal With Issues With Expedited Clearance

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Merck and Orion Announce Global Collaboration for Oncology Drug

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

First Patient Adopting TAC-001 Has Been Announced By Tallac

Content Team by Content Team
1st August 2022
in Clinical Trials, News
First Patient Adopting TAC-001 Has Been Announced By Tallac

In a phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumours, Tallac Therapeutics has reported that the first patient has received treatment with TAC-001. TAC-001 is the first clinical candidate from the company’s innovative toll-like receptor agonist antibody conjugate (TRAAC) system to enter the clinic.

According to Hong Wan, chief executive officer of Tallac, the beginning of the first-in-human study for their main therapeutic candidate is a critical milestone for Tallac as they continue to expand their differentiated portfolio of immunotherapy medicines generated from their TRAAC technology.

They are advancing extra resources in their pipeline as this study progresses, and they intend to submit an investigational new medication application at the start of next year for the phase 1 study. This therapeutic candidate targets dendritic cells via SIRP-alpha receptors and is a systemically administered toll-like receptor 9 agonist, Wan continued.

For patients with specific advanced or metastatic solid tumours, the phase 1/2 experiment known as INCLINE-101 is an open-label, multi-center, dose progression and extension study of TAC-001. Its purpose is to assess the intravenously administered TAC-001’s safety, pharmacokinetics, and preliminary anti-tumor activity.

According to Candy Bermingham, vice president of clinical science at Tallac, TAC-001 is distinctive in that it combines B cells and TLR9 activation to generate adaptive and innate immune anti-tumor immune function and has in preclinical trials shown significant single-agent effectiveness. They look forward to gaining a better understanding of the clinical efficacy of TAC-001 in progressing solid tumours and the possibility of such a chemical to address the significant unmet therapeutic requirements that still exist in a variety of cancer types.

Immunotherapies known as toll-like receptor 9 (TLR9) agonists produce combined innate and adaptive immune responses, which may result in more potent and long-lasting anti-cancer immunity to assist in combating resistance to conventional oncology treatments.

When given intratumorally, TLR9 agonists have shown clinical activity in melanoma patients. B cells, which mostly associate with tertiary lymphoid structures and express TLR9 and play a crucial role in the immune system, constitute a significant part of the tertiary lymphoid structure (TLS). In many different types of solid tumours, the presence of B cells and TLS is a favourable prognostic feature and predicts the therapeutic response to checkpoint inhibitors.

Previous Post

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

Next Post

Data For Treatment of Schizophrenia Disclosed By Cyclerion

Related Posts

Moderna To introduce The Fusion Of COVID-19 And Flu Booster
Drug Development

September May See Advent of Revised COVID-19 Booster Shots

1st August 2022
Data For Treatment of Schizophrenia Disclosed By Cyclerion
IPR Data Management

Data For Treatment of Schizophrenia Disclosed By Cyclerion

1st August 2022
Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream
FDA Approvals

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

1st August 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
FDA Approvals

FDA Continues To Deal With Issues With Expedited Clearance

1st August 2022
Test For Sterility of Cell Culture Using Ratio of NA To NAM
Drug Development

Test For Sterility of Cell Culture Using Ratio of NA To NAM

1st August 2022
Authorities Agree To Work Together Towards Integrating RWE
IPR Data Management

Authorities Agree To Work Together Towards Integrating RWE

1st August 2022
Next Post
Data For Treatment of Schizophrenia Disclosed By Cyclerion

Data For Treatment of Schizophrenia Disclosed By Cyclerion

Latest News

Moderna To introduce The Fusion Of COVID-19 And Flu Booster
Drug Development

September May See Advent of Revised COVID-19 Booster Shots

1st August 2022
Data For Treatment of Schizophrenia Disclosed By Cyclerion
IPR Data Management

Data For Treatment of Schizophrenia Disclosed By Cyclerion

1st August 2022
First Patient Adopting TAC-001 Has Been Announced By Tallac
Clinical Trials

First Patient Adopting TAC-001 Has Been Announced By Tallac

1st August 2022
Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream
FDA Approvals

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

1st August 2022
BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
Press Statements

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

1st August 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In